Table 3.
Sample Physician-Generated Twitter Content
| 2010 |
2011 |
||
|---|---|---|---|
| Tweet | Author @ | Tweet | Author @ |
| RT @MaverickNY: Ipilimumab data looks promising in melanoma, but 1.5% death rate frm bowel perforation, immune response is a worry. Remember TGN1412 #asco10 | drsteventucker | Overall, amrubicin v topotecan trial reminds me of topo v CAV in SCLC, or pemetrexed v docetaxel in NSCLC. I'd welcome amru option. #ASCO11 | JackWestMD |
| Great results but how to reconcile with earlier neg Ipi trials? RT @matthewherper: Bristol’s Big Win http://bit.ly/c62GMI #asco10 #melanoma | melanoma_Drs | @TTalessandroTT I totally agree. For bevacizumab, any trial is not good enough with PFS. Need improved survival improvement. #ASCO11 | teamoncology |
| HLA A2 only, 50% of pts. I think yes. RT @BiotechStockRsr: ipi trial HLA restricted. Will FDA label have restriction? #asco10 #melanoma | melanoma_Drs | Despite heavy pretreatment pts had 61% response and durable responses to Crizotinib #ASCO11 | weldeiry |
| If Ipi approved based on this trial, would/should it be used first line therapy? #asco10 #melanoma | melanoma_Drs | #ASCO11 #myeloma lenalidomide assoc second primary malignancies seems assoc w Len-Mel and not Len-dex. Benefit of Len for MM ctrl > risk | mtmdphd |
| If pending Ipi/DTIC versus DTIC study negative when analyzed, how should we view this study as DTIC better control arm? #asco10 #melanoma | melanoma_Drs | Anti-BCL2 obatoclax trial fails to show signif benefit in OS, but trends toward better RR, PFS, & OS in recipients of obatoclax. #ASCO11 | JackWestMD |
| Sondak: Ipi optimal dose unknown with many different doses done in various trials #asco10 #melanoma | melanoma_Drs | The benefits of Zolindonic Acid on SRE in MM or solid tumors far out weigh risks inherent. #ASCO11 A comforting palliation. | JediPD |
| Abstract #004: impressive improv in overall survival with ipilimumab for melanoma. But study was restricted to HLA-A*0201 patients #asco10 | mfenner | Second post-plenary thought: #melanoma thought–should dtic be added to Ippi–i don't think so, stays monotherapy #asco11 | Melanoma_doctor |
| RT @Melanoma_doctor Sondak: ipi is toxic beyond that what med oncs used to. Training essential. Deaths even with experienced docs #asco10 | teamoncology | #ASCO11 randomized phase III pazopanib versus placebo in metastatic soft tissue sarcoma progressed on chemo 3 fold PFS benefit. | alantanmd |
| My No. 1 ASCO news: Phase III Ipilimumab, with/or w/out gp100 peptide vax v. vax, improved survival in met melanoma. #asco10 immunotherapy | teamoncology | No definitive evidence that oxaliplatin effective in stage II colon ca even if hi and low risk stage II evaluated #ASCO11 | weldeiry |